Showing results (481-490 of 554) with videos related to

Sort By:
Pageof 56
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideD E Rathkopf, M R Smith, C J Ryan, et al.
European Urology Oncology|February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on DarolutamideBarak Talmor, Carole A Harris, Christopher Gianacas, et al.
Oncotarget|February 3, 2017
Detection fidelity of AR mutations in plasma derived cell-free DNAAlexa Goldstein, Patricia Valda Toro, Justin Lee, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Cancer|March 25, 2022
Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancerAdrianna A Mendes, Jiayun Lu, Harsimar B Kaur, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2023
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate CancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Oncotarget|April 9, 2026
CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancerAllison Makovec, John T Phoenix, Hannah E Bergom, et al.
Pageof 56